NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter

NovaDel CEO to Be Interviewed Tomorrow by Wall St. Reporter 


FEMINGTON, N.J., April 15  /PRNewswire-FirstCall/ -- Gary Shangold, MD, chief
executive officer of NovaDel Pharma, Inc.  (BULLETIN BOARD: NVDL) , will be
interviewed by Wall Street Reporter, a web-based financial site, tomorrow
morning, Friday April 16.

Dr. Shangold will provide an update on the regulatory filing plans for the
company's first lingual spray product and discuss the status of product
development programs for the company's Tier One candidates.  These include
lingual spray formulations of Zofran(R) (ondansetron), the leading anti-emetic
marketed in the US by GlaxoSmithKline, Imitrex(R) (sumatriptan) also marketed
in the US by GlaxoSmithKline, Ambien(R) (zolpidem) marketed in the US by
Sanofi, and Xanax(R) (alprazolam), which is sold by Pfizer and several generic
producers.

To listen to the interview, visit http://www.wallstreetreporter.com/.  The
interview is expected to be posted by 11:00 a.m. EDT, Friday, April 16.

About NovaDel Pharma Inc.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and
over-the-counter drugs.  The Company's proprietary lingual spray technology
delivery system offers the patient (i) fast onset of action; (ii) improved drug
safety by reducing the required drug dosage and reducing side effects; (iii)
improved patient convenience and compliance; and (iv) enhanced dosage
reliability.  The Company plans to develop such products independently and
through collaborative arrangements with major pharmaceutical and biotech
companies.

Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the ability to develop products (independently and through
collaborative arrangements), and the ability to commercialize and obtain
approval for products under development. Further, the Company operates in
industries where securities may be volatile and may be influenced by regulatory
and other factors beyond the Company's control. Important factors that the
Company believes might cause such differences are discussed in the risk factors
detailed in the Company's most recent Annual Report and Registration
Statements, filed with the Securities and Exchange Commission.  In assessing
forward-looking statements contained herein, if any, the reader is urged to
carefully read all cautionary statements contained in such filings.

   Contact:
   Barry C. Cohen
   VP Business & New Product Development
   908 782-3431 x 2160
   NovaDel Pharma Inc.

   Thomas Redington
   203 222-7399
   212 926-1733
   

DATASOURCE: NovaDel Pharma, Inc.



CONTACT:  Barry C. Cohen, VP Business & New Product Development of

NovaDel Pharma Inc., [phone], ext. 2160; or Thomas Redington,

[phone], [phone], , for NovaDel

Pharma, Inc.



Web site:  http://www.wallstreetreporter.com/ 

Copyright